8 Myths of Pre-Seed Venture Investing
I’ve been investing at the pre-seed for the last 7 years. First through the Techstars NYC and now as a Managing Partner at 2048 Ventures.
Pre-seed investing presents a unique set of challenges as compared to later stage (series A+) venture investing: the signals, the data, and the strategy could not be more different.
Like every industry, venture capital has tried and true advice that is often passed around between fund managers. But, like in every other industry, the advice needs to be contextualized.
In the same way that you would not apply the enterprise sales playbook when running an SMB SaaS company, the strategies and methods used by Series A firms do not apply to pre-seed. In fact, they often can be the opposite of what makes sense.
Share this article
MONTRÉAL, Jan. 21, 2021 /PRNewswire/ -
Eli, a company enabling women to own their fertility and health decisions with a novel hormone tracking technology, today announced its $1.5 million USD seed round co-led by Vectr Ventures and 2048 Ventures. The round closed in December 2020 with the participation of Real Ventures, Techstars, Panache Ventures, Ramen Ventures, MEDTEQ+, and serial entrepreneur Steven Arless, who also joined the board.The round brings the company s total funding since its creation in mid-2019 to $2.1 million USD. This amount includes a previous investment from Techstars and Real Ventures via Techstars Montréal AI. Hormones are core to women s fertility and general health, yet they remain a black box. We are unlocking that box and empowering women to have access to their own hormone data daily,
Eli raises $1.9 million CAD in seed funding to develop at-home hormone monitoring tech
Eli Science Inc. has raised a $1.9 million CAD ($1.5 million USD) seed round to target the historically underserved women’s healthtech market via its saliva-based daily hormone tracking technology.
The round, which was co-led by Hong Kong’s Vectr Ventures and 2048 Ventures, closed in late December 2020. Other investors included Real Ventures, Techstars, Panache Ventures, Ramen Ventures, MEDTEQ+, and Steven Arless, who joined Eli Health’s board of directors. To date, the company has raised a total of $2.1 million USD, including prior investments from Techstars and Real Ventures through Techstars Montreal AI accelerator.